James Lingeman, MD
Urology · Indianapolis, INNPI 1316947096
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Boston Scientific at 57.9% of the total. Reporting peaked in 2022 at $4,488 and has fallen 93.6% since, to $285 in 2025.
Across 38 payments — averaging $261.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Alnylam Pharmaceuticals Inc.$3K
- C. R. Bard, Inc. & Subsidiaries$201
- Medical Device Business Services, Inc.$150
- Richard Wolf Medical Instruments Corp.$117
- Ambu Inc.$115
- plus $121 from 2 others
Across 5 payments — averaging $2480.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procept Biorobotics Corporation$10K
- Alnylam Pharmaceuticals Inc.$2K
What the payments were for
- Consulting fees$3,72538%
- Speaking & faculty fees$4,14042%
- Food & beverage$1,98520%
- Education$831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $5,753 |
| Alnylam Pharmaceuticals Inc. | 1 | $3,475 |
| C. R. Bard, Inc. & Subsidiaries | 15 | $201 |
| Medical Device Business Services, Inc. | 1 | $150 |
| Richard Wolf Medical Instruments Corp. | 1 | $117 |
| Ambu Inc. | 1 | $115 |
| Astellas Pharma US Inc | 1 | $83 |
| Calyxo, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXLUMO$3,475
- GENERAL BPH$3,240
- LithoVue$1,043
- GENERAL KIDNEY STONE DISEASE$741
- Medical Instrumentation$117
How this compares
$9,932 in reported general payments places this provider in the 75th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 47 | $416,422 |
| MyrbetriqMirabegron | 56 | $42,344 |
| Potassium Citrate ErPotassium Citrate | 61 | $10,414 |
| Potassium Chloride | 124 | $5,457 |
| Testosterone | 16 | $4,357 |
| Tamsulosin Hcl | 166 | $2,840 |
| Duloxetine Hcl | 67 | $2,029 |
| Chlorthalidone | 116 | $2,011 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,960 |
| Indapamide | 144 | $1,759 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 106 | $1,510 |
| Klor-Con M20Potassium Chloride | 88 | $1,409 |
| Amiloride-HydrochlorothiazideAmiloride/Hydrochlorothiazide | 19 | $1,308 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 87 | $682 |
| Allopurinol | 62 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $83 | $42,34456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 272 urology providers in Indiana.
Other urology in Indianapolis
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Helen BernieIndianapolis$100K
- Austen SladeIndianapolis$73K
- Jacob RustIndianapolis$57K
- Alvin WeeIndianapolis$46K
- Jason SprungerIndianapolis$30K
- Steven KheyfetsIndianapolis$18K
- Hristos KaimakliotisIndianapolis$12K
- Adri DurantIndianapolis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.